Find disease awareness content and relevant supporting materials
Increased expression of miR-153 predicts poor prognosis for patients with prostate cancer.
Deregulation of miR-153 has recently been observed in several common human cancer, while miR-153 serves an oncogene or tumor suppressive role in different cancer types. Previously, miR-153 has been identified to be overexpressed in...
MLHW (Japan) approves Keytruda + chemotherapy to treat triple negative breast cancer
Merck Inc., announced that Keytruda Merck’s anti-PD-1 therapy, received four new approvals from Japan’s Ministry of Health, Labor and Welfare (MHLW) including Keytruda in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery for patients with hormone receptor-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer at high risk of recurrence, based on data from the KEYNOTE-522 trial
Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
Purpose: The main objective of our study was to explore changes in the expression levels of differentially expressed genes associated with prostate cancer progression and to design a series of experiments to verify the function of...
Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer
PART I - Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer
The goal of this clinical study PART I is to determine impact of radiotherapy treatment in combination with...